Drug Screen 9 Panel, Serum or Plasma - Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation
Monitor patient compliance.
Qualitative Enzyme-Linked Immunosorbent Assay/ Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Confirmation: 1-4 days
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).
Remove plasma from cells ASAP or within 2 hours of collection. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 3 mL) Also acceptable: Serum.
Specimens exposed to repeated freeze/thaw cycles. Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate).
Cocaine and cocaethylene are more stable in fluoride-preserved plasma than serum.
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years
|Drugs Covered and Cutoff Concentrations
|Buprenorphine||Effective Aug 15, 2016
Drugs/Drug classes reported as "Positive" are automatically reflexed to mass spectrometry confirmation/quantitation. An unconfirmed positive immunoassay screen result may be useful for medical purposes but does not meet forensic standards. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are automatically reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Screen-positive specimens are automatically confirmed by GC/MS and/or LC-MS/MS; additional charges may apply.
80307; if reflexed, add 80324; 80345; 80346; 80348; 80349; 80353; 80358; 80359; 80361; 80365; 83992 (Reflexed Alt Code: G0480 )
|Component Test Code*||Component Chart Name||LOINC|
|0092419||Drug Screen Comments, Serum or Plasma||48767-8|
|0092421||Cannabinoids, S/P, Screen||8172-9|
|0092422||Cocaine, S/P, Screen||8191-9|
|0092423||Opiates, S/P, Screen||8219-8|
|0092424||Phencyclidine, S/P, Screen||8236-2|
|0092425||Amphetamines, S/P, Screen||8149-7|
|0092426||Barbiturates, S/P, Screen||20421-4|
|0092427||Benzodiazepines, S/P, Screen||46976-7|
|0092428||Methadone, S/P, Screen||59705-4|
|0092430||Oxycodone, S/P, Screen||13576-4|
|0093414||Methamphetamine, S/P, Screen||3777-0|
|2013568||Buprenorphine, S/P, Screen||3413-2|
- Pain Management